3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Carcinoma, Renal Cell
11
Sarcoma
6
Neoplasms
6
Lymphoma, Mantle-Cell
6
Prostatic Neoplasms
5
Lymphoma, Non-Hodgkin
5
Rhabdomyosarcoma
4
Neoplasm Metastasis
4
Kidney Neoplasms
4
Gliosarcoma
4
Glioblastoma
4
Breast Neoplasms
4
Brain Neoplasms
4
Waldenstrom Macroglobulinemia
3
Osteosarcoma
3
Melanoma
3
Lymphoma, Follicular
3
Lymphoma, B-Cell, Marginal Zone
3
Endometrial Neoplasms
3
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Ovarian Neoplasms
2
Oligodendroglioma
2
Neuroectodermal Tumors, Primitive, Peripheral
2
Neuroblastoma
2
Liposarcoma
2
Leukemia, Lymphocytic, Chronic, B-Cell
2
Leukemia
2
Glioma
2
Fallopian Tube Neoplasms
2
Carcinoma, Hepatocellular
2
Interventions
Sunitinib
2
Paclitaxel
2
valrubicin
1
temsirolimus
1
sipuleucel-T
1
luprolide acetate gel depot
1
ferumoxtran-10
1
abiraterone
1
abemaciclib
1
Suspensions
1
Surveys and Questionnaires
1
Standard of Care
1
Radiotherapy
1
Prednisone
1
Prednisolone
1
Powders
1
Pemetrexed
1
Neoadjuvant Therapy
1
National Cancer Institute (U.S.)
1
Mitomycin
1
Magnetic Resonance Spectroscopy
1
Leuprolide
1
Fatty Acids, Omega-3
1
Educational Status
1
Docetaxel
1
Bevacizumab
1
Atorvastatin
1
Administration, Intravesical
1
2-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Urogenital Neoplasms
×
temsirolimus
×
Clear all
NCT00631371
2016-04-27
INTORACT
Pfizer
Phase 3
Completed
791 enrolled
11 charts